

EyePoint, Inc. (EYPT)

Nasdaq; business equipment; SIC 3826, Laboratory Analytical Instruments; CIK 0001314102

[illegible]

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E? technology (Durasert E?) for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU?1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible

Durasert E? drug delivery technology.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 88.9						
Gross profitability		not computable	28.5%			one or more required annual facts are missing a prior annual debt, equity, and cash observation is required
Return on invested capital		not computable	10.9%			required
Accruals ratio		2.1%	(7.4%)	88.9	621	2025-12-31
Gross margin stability, five years		not computable	2.4 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 57.3						
Twelve-month failure probability		0.67%	0.05%	92.0	101	2026-06-30
Altman Z double-prime		(3.58)	2.18	71.5	566	2025-12-31
Net debt to EBITDA		not computable	1.11x			EBITDA must exceed \$100,000 latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Interest coverage		not computable	3.77x			
Current ratio		8.88x	2.02x	8.4	666	2025-12-31
Growth and financing, sleeve percentile 60.6						
Revenue growth, three-year compound		(8.8%)	6.4%	85.5	538	2025-12-31
Free cash flow growth, three-year compound		not computable	17.2%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	14.3%			
Asset growth, three years		26.4%	5.0%	11.2	563	2025-12-31
Net share issuance, one year		21.4%	0.5%	85.0	407	2026-02-27


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 5.0 months
Fortress balance sheet	cash minus debt is 65,633,000 USD; Altman Z is not used

Among 497 peers

business equipment; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
456	Hewlett Packard Enterprise Co. (HPE)	91.8	E	
457	Hewlett Packard Enterprise Co. (HPE-PC)	91.8	E	
458	Atomera Inc. (ATOM)	92.1	E	dilution, degenerate inputs
459	RideNow Group, Inc. (RDNW)	92.3	E	
460	Quantum Corp. (QMCO)	92.5	E	dilution, late filer
461	EyePoint, Inc. (EYPT) <	92.7	E	short runway, fortress balance sheet
462	Bridgeline Digital, Inc. (BLIN)	92.9	E	fortress balance sheet
463	Upland Software, Inc. (UPLD)	93.1	E	
464	Inseego Corp. (INSG)	93.3	E	short runway
465	3D Systems Corp. (DDD)	93.5	E	late filer
466	Professional Diversity Network, Inc. (IPDN)	93.8	E	dilution, short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(68.4%)	2.2%	6
Distance from 52-week high	(81.6%)	(30.0%)	7
EBIT to enterprise value	(111.8%)	1.5%	4
Free cash flow yield	(81.6%)	2.7%	4
Book value to price	0.56	0.23	76
Sales to price	0.11	0.30	21
Composite equity issuance, five years	109.8%	3.9%	93
Relative strength against the sector, log excess return	(1.43)	(0.26)	6

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$110.5M
Operating cash flow, four quarters	-\$267.3M
Months of runway	5.0
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$17.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-\$99.6M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$10.3M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2022-12-31	2023-03-10	10-K	0000950170-23-007180
4	total debt	us-gaap:LongTermDebt	\$30.0M	2022-12-31	2023-03-10	10-K	0000950170-23-007180
5	book equity	us-gaap:StockholdersEquity	\$96.4M	2022-12-31	2025-03-06	10-K	0000950170-25-034601
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$95.6M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
7	net income	us-gaap:NetIncomeLoss	-\$232.0M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
8	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$240.1M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
9	assets	us-gaap:Assets	\$364.0M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
10	assets	us-gaap:Assets	\$418.5M	2024-12-31	2026-03-05	10-K	0001193125-26-093917
11	current assets	us-gaap:AssetsCurrent	\$328.7M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
12	current liabilities	us-gaap:LiabilitiesCurrent	\$37.0M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
13	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.1B	2025-12-31	2026-03-05	10-K	0001193125-26-093917
14	operating income	us-gaap:OperatingIncomeLoss	-\$243.4M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
15	book equity	us-gaap:StockholdersEquity	\$306.1M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
16	liabilities	us-gaap:Liabilities	\$57.9M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
17	depreciation amortization	us-gaap:Depreciation	\$396,000	2022-12-31	2024-03-08	10-K	0000950170-24-028523
18	operating income	us-gaap:OperatingIncomeLoss	-\$75.1M	2023-12-31	2025-03-06	10-K	0000950170-25-034601
19	interest expense	us-gaap:InterestExpense	\$1.2M	2023-12-31	2024-03-08	10-K	0000950170-24-028523
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$31.4M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$43.3M	2024-12-31	2026-03-05	10-K	0001193125-26-093917
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$46.0M	2023-12-31	2025-03-06	10-K	0000950170-25-034601
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$41.4M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.3M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$126.2M	2024-12-31	2026-03-05	10-K	0001193125-26-093917
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.1M	2024-12-31	2026-03-05	10-K	0001193125-26-093917
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.9M	2023-12-31	2025-03-06	10-K	0000950170-25-034601
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.5M	2023-12-31	2025-03-06	10-K	0000950170-25-034601
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$65.0M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.1M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
31	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$2.3M	2025-12-31	2026-03-05	10-K	0001193125-26-093917
32	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$21.7M	2022-12-31	2024-03-05	10-K	0001193125-26-093917
33	income tax	us-gaap:IncomeTaxExpenseBenefit	\$279,000	2025-12-31	2026-03-05	10-K	0001193125-26-093917
34	current assets	us-gaap:AssetsCurrent	\$383.3M	2024-12-31	2026-03-05	10-K	0001193125-26-093917
35	current liabilities	us-gaap:LiabilitiesCurrent	\$49.0M	2024-12-31	2026-03-05	10-K	0001193125-26-093917
36	assets	us-gaap:Assets	\$355.2M	2023-12-31	2025-03-06	10-K	0000950170-25-034601
37	assets	us-gaap:Assets	\$180.4M	2022-12-31	2024-03-08	10-K	0000950170-24-028523
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	83,431,950	2026-02-27	2026-03-05	10-K	0001193125-26-093917
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,728,760	2025-02-28	2025-03-06	10-K	0000950170-25-034601